ESC Premium Access

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Congress Session

About the speaker

Mr Qidi Ying

Royal Perth Hospital, Perth (Australia)
0 follower

17 more presentations in this session

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Speaker: Doctor M. Delbeck (Wuppertal, DE)

Thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Speaker: Assistant Professor H. Fukaya (Sagamihara, JP)

Thumbnail

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

Speaker: Doctor Y. Lenz (Berlin, DE)

Thumbnail

Access the full session

Congress committee e-posters choice in pharmacology and pharmacotherapy

Speakers: Mr Q. Ying, Mr A. Holt, Mr A. Holt, Doctor M. Delbeck, Assistant Professor H. Fukaya...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

The novel ageing-induced long non-coding RNA MIRIAL controls endothelial cell and mitochondrial function

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

This platform is supported by

logo Novo Nordisk